Sign inJoin waitlistJoin the waitlist

SS

Stephen Strickland

Physician · Verdi Oncology Tennessee PC

Credentials: · · ·

History

Verdi Oncology Tennessee PC
2026–Present

Vanderbilt University Medical Center
2005–2006
Internal Medicine
Vanderbilt University Medical Center
2002–2005
Louisiana State Univ Sch of Med in New Orleans
1998–2002

Research

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid…
Journal of Clinical Oncology · 2018 · 802 citations
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Journal of Clinical Oncology · 2019 · 557 citations
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
The Lancet Oncology · 2017 · 424 citations

Eunice Wang
13 papers
JL
Jeffrey Lancet
13 papers
Gary Schiller
11 papers
Jessica Altman
11 papers
Richard Stone
11 papers
Sanjay Mohan
11 papers
MT
Martin Tallman
10 papers
Michael Savona
10 papers
Alexander Perl
9 papers
Mark Litzow
9 papers
Frederick Appelbaum
8 papers
Gail Roboz
8 papers

Clinical trials

A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia
Principal investigator · Withdrawn · Phase 2
Vanderbilt-Ingram Cancer Center
2007–2009
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Site PI · Recruiting · Phase 1
Crossbow Therapeutics, Inc.
2025–2027
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Site PI · Recruiting · Phase 2
Allotera Therapeutics
2025–2028
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Site PI · Recruiting · Phase 1
SystImmune Inc.
2024–2027